Saied Mushtagh, ND

 

Patients with paresthesias and nonspecific white matter hyperintensities often present diagnostic challenges when imaging is inconclusive for multiple sclerosis. This review examines differential diagnosis, neurologic risk stratification, and the cautious use of environmental exposure history and urinary mycotoxin screening as hypothesis-generating tools within an integrative clinical framework.

Could environmental factors contribute to persistent neurologic symptoms when multiple sclerosis remains unconfirmed? This narrative review explores the evaluation of paresthesias with nonspecific white matter hyperintensities, highlighting differential diagnosis, correction of modifiable risk factors, and the potential role of environmental mycotoxin screening while emphasizing the importance of careful interpretation and shared decision-making.

In this case, a female in her late 30s presented with episodic paresthesias (tingling, numbness, and burning sensations) affecting the distal extremities, initially remitting for approximately two years before recurring with greater intensity. Symptoms were accompanied by intermittent calf stiffness and “rush” sensations in the legs upon standing after prolonged sitting (e.g., driving), as well as persistent morning finger tingling. Given the sensory distribution and recurrence pattern, the patient experienced significant health anxiety, particularly due to concern for demyelinating disease. Additional history included longstanding sleep disturbance with nocturnal awakenings, episodes of drenching night sweats, and a pattern of irregular heavy menstrual bleeding with clots, contributing to iron depletion over time. Family and psychosocial stressors were notable, including a mother diagnosed with Parkinson’s disease and a sister undergoing chemotherapy, which the patient described as traumatic and contributing to hypervigilance about bodily sensations.

Neurologic imaging was pursued to evaluate for multiple sclerosis (MS). A prior MRI of the head and cervical/thoracic spine (2019) showed no evidence of demyelinating plaques and no MS lesions in the cervical spine; mild central canal narrowing at C5/6 due to a small posterior disc protrusion was noted without neural compression, along with mild generalized thoracic degenerative disc disease. A subsequent brain MRI without contrast (February 2021) identified several tiny deep white matter hyperintensities: three in the left cerebral hemisphere (one 4 mm lesion in the parietal lobe and two adjacent ~1.5 mm lesions in the temporal lobe) and one tiny lesion in the deep white matter of the right parietal lobe. Importantly, these lesions were described as nonspecific, not in an immediately periventricular location, and “certainly not diagnostic of MS at this point in time,” with the radiologist noting that close follow-up imaging could be considered if clinical suspicion remained high. Collectively, the imaging findings supported a working impression of possible preclinical MS versus nonspecific white matter change in the context of sensory symptoms, while not meeting diagnostic criteria based on imaging alone.

Given the patient’s report of potential indoor mold exposure (mold identified in a cleaned washing machine, with no visible mold on current windowsills) and the persistence of neurologic symptoms despite nondiagnostic imaging, environmental mycotoxin screening was pursued as part of a broader naturopathic assessment. Urinary mycotoxin testing (April 2021) demonstrated elevated ochratoxin A (15.26; reference <7.5) and elevated mycophenolic acid (50.68; reference <37.4), with other measured metabolites within reported reference ranges (aflatoxin M1 0.00; sterigmatocystin 0.00; gliotoxin <200). Additional toxicant screening showed 2-hydroxyisobutyric acid (2HIB) at 7,089 µg/g creatinine (near the 75th percentile marker on the report), with monoethylphthalate (MEP) and 2,3,4-methylhippuric acid (2,3,4-MHA) not elevated relative to percentile markers. A glyphosate screen reported a value of 2.4 µg/g creatinine (95% of reference range). These findings were interpreted cautiously as evidence of increased exposure or excretion of select environmental metabolites rather than proof of causality. However, they provided a clinically relevant avenue for patient-centered risk assessment and environmental history refinement in a symptomatic patient concerned about neuroinflammation and possible demyelinating disease.

Concurrently, laboratory evaluation identified significant iron depletion without anemia, consistent with the patient’s heavy irregular menses. Ferritin was markedly low at 6 µg/L (reference 15–247) while hemoglobin (133 g/L) and indices (MCV 84 fL) remained within reference ranges. Mild neutropenia was present (neutrophils 1.9 ×10^9/L; reference 2.0–7.5). Vitamin D was low at 30 nmol/L (reference 75–150). Reproductive hormone testing on cycle day 3 showed FSH 5.5 IU/L and LH 5.5 IU/L, with estradiol 150 pmol/L—findings not suggestive of menopause biochemically, supporting the interpretation that vasomotor symptoms and cycle irregularity warranted a broader differential (e.g., stress physiology, iron deficiency, sleep disruption) rather than being attributed solely to menopausal transition.

Given some recent evidence points to higher fungal diversity and richness in MS patients compared to controls¹, this case highlights a common clinical scenario in which patients present with neurologic sensory symptoms and nonspecific white matter hyperintensities that do not meet diagnostic criteria for MS yet still generate substantial distress and ongoing symptom monitoring. From a naturopathic perspective, the workup emphasized both biomedical risk stratification (imaging, iron status, vitamin D) and individualized exploration of potential environmental contributors. While the relationship between indoor mold exposure, urinary mycotoxin biomarkers, and demyelinating disease remains an area of ongoing debate and limited consensus, targeted screening may serve as a pragmatic tool for hypothesis generation, environmental counselling, and shared decision-making—particularly in patients with persistent neurologic symptoms, nondiagnostic imaging, and a history suggestive of potential exposure. Future directions include careful clinical follow-up, consideration of repeat MRI if symptoms evolve, and structured interventions addressing modifiable contributors to neuroimmune resilience (sleep restoration, correction of iron deficiency and vitamin D insufficiency, and environmental exposure mitigation where indicated)

 

Paresthesias With Nonspecific White Matter Hyperintensities: A Narrative Review of Differential Diagnosis and the Cautious Role of Environmental Mycotoxin Screening in Possible Preclinical Multiple Sclerosis

Patients with intermittent paresthesias and magnetic resonance imaging (MRI) findings of small, nonspecific white matter hyperintensities (WMH) commonly present with concern for multiple sclerosis (MS). When imaging is nondiagnostic, clinicians must balance appropriate neurologic risk stratification with a broad differential diagnosis and pragmatic attention to modifiable contributors such as mineral deficiency, vitamin D insufficiency, sleep disruption, and psychosocial stress. In parallel, some patients report potential indoor dampness or mold exposure and pursue urinary mycotoxin testing. This narrative review summarizes:

(1) interpretation of nonspecific WMH in the context of sensory symptoms and possible preclinical MS, (2) common non-MS contributors to paresthesias that merit systematic screening, and (3) a cautious approach to environmental exposure history and urinary mycotoxin screening as hypothesis-generating tools rather than confirmatory diagnostics. Practical considerations for patient communication, shared decision-making, and follow-up planning are provided.

Paresthesias—tingling, numbness, burning, or “pins and needles”—are frequent neurologic complaints in primary care and naturopathic practice. The symptom is nonspecific: it may reflect peripheral nerve irritation, metabolic or nutrient deficiency, sleep disruption, anxiety physiology, medication effects, or central nervous system pathology. Clinical complexity increases when paresthesias recur episodically, involve multiple limbs, or are accompanied by WMH on MRI. In such cases, patient distress can become a dominant clinical feature, particularly when demyelinating disease is feared.

MS is a chronic immune-mediated disorder of the central nervous system with heterogeneous presentations and a diagnostic process that can be prolonged. Many patients undergo neuroimaging during a period of uncertainty in which symptoms are real and function-limiting but do not meet criteria for MS. The concept of a prodromal or preclinical phase of MS is increasingly discussed in neuroimmunology, with attention to immune pathways, environmental exposures, and early clinical signals. However, “preclinical MS” language can be problematic in patient-facing contexts if it is interpreted as a diagnosis rather than a risk state.

Alongside neurologic risk stratification, clinicians can often identify modifiable contributors that amplify sensory symptoms or symptom perception, including iron depletion (often without anemia), vitamin D insufficiency, sleep fragmentation, hyperventilation or panic physiology, and chronic stress. A subset of patients also report potential indoor dampness or mold exposure and seek urinary mycotoxin testing. The relationship between indoor mold, urinary mycotoxin biomarkers, and neuroinflammatory disease remains an area of evolving evidence and debate. Nevertheless, clinicians benefit from a structured approach that avoids over-attribution while still addressing patient concerns and modifiable environmental risks.

 

Interpreting Nonspecific WMH in Patients Concerned About MS

What “Nonspecific WMH” Typically Means

WMH on T2/FLAIR sequences are common radiologic findings. They may be incidental, age-associated, or related to migraine, microvascular change, prior inflammation, trauma, metabolic factors, or normal variants. Radiology reports often use “nonspecific” to indicate that lesions do not show a pattern typical of demyelinating disease. In practice, this term can be reassuring to clinicians but confusing to patients, who may interpret any “white matter lesion” as evidence of MS.

A practical clinical approach is to translate imaging language into patient-centered meaning: “These spots are common and can have many causes; the pattern does not currently support MS.” This framing validates the concern while emphasizing that lesion pattern and clinical correlation matter.

 

When WMH Increases Suspicion for Demyelinating Disease

Suspicion for MS is strengthened by lesion morphology and distribution consistent with demyelination, dissemination in space and time, and a neurologic history consistent with demyelinating events. Conversely, a small number of tiny deep WMH without characteristic distribution may be interpreted as low-specificity findings. In such situations, clinicians can still outline a rational monitoring plan: symptom tracking, neurologic examination, and repeat imaging only when clinically justified.

 

“Possible Preclinical MS” and Careful Language

The idea of prodromal or preclinical MS is increasingly explored. In academic writing, “preclinical” may refer to immunologic or clinical changes that precede diagnosis. In clinical communication, however, the term can inadvertently intensify anxiety and drive excessive testing. A balanced approach is to describe the situation as “MS not supported by current imaging; follow-up depends on symptom evolution and neurologic assessment,” while acknowledging that some individuals require longitudinal observation.

 

Differential Diagnosis of Paresthesias When MS Is Not Confirmed

A structured differential reduces premature closure on MS or environmental explanations and helps clinicians identify treatable contributors.

 

Nutrient and Hematologic Contributors

• Iron deficiency without anemia: Ferritin can be markedly low despite normal hemoglobin and indices. Iron depletion may contribute to fatigue, sleep disruption, restless legs–type symptoms, impaired stress tolerance, and heightened physiologic reactivity. In menstruating patients with heavy or irregular bleeding, iron deficiency is common and clinically actionable. Evaluation should include bleeding history and appropriate gynecologic assessment when indicated.
• Vitamin D insufficiency/deficiency: Low 25-hydroxyvitamin D is common and may coexist with fatigue, mood symptoms, and musculoskeletal pain. Vitamin D status is also frequently discussed in MS risk and immune regulation, though clinical implications vary and supplementation should follow standard safety considerations.
• Vitamin B12/folate and related markers: B12 deficiency can present with paresthesias and should be assessed with appropriate confirmatory testing when indicated. Clinicians may consider methylmalonic acid or homocysteine in equivocal cases.
• Magnesium and other micronutrients: While less specific, magnesium status and dietary adequacy may be relevant in patients with muscle symptoms, sleep disturbance, and high stress.

 

Endocrine and Metabolic Contributors

• Thyroid dysfunction: Hypothyroidism can contribute to neuropathic symptoms, fatigue, and mood disturbance. Screening with thyroid-stimulating hormone (and additional markers when indicated) is common.
• Glucose dysregulation: Prediabetes/diabetes can cause peripheral neuropathy. Screening with fasting glucose and/or A1c is often warranted, particularly when symptoms are distal and persistent.

 

Mechanical and Neurologic Contributors

• Cervical spine pathology: Disc protrusion or canal narrowing may contribute to sensory symptoms depending on severity and clinical correlation. Even mild findings can become clinically relevant in the presence of postural strain, muscle tension, or nerve irritation.
• Peripheral nerve entrapment: Carpal tunnel syndrome and other entrapments can cause morning tingling or positional symptoms. Clinical examination and, when indicated, nerve conduction studies may clarify etiology.

 

Psychophysiologic Contributors

• Sleep fragmentation and hyperarousal: Insomnia and nocturnal awakenings can amplify pain perception, paresthesias, and anxiety. Poor sleep also reduces coping capacity and increases symptom monitoring.
• Anxiety and hyperventilation physiology: Panic physiology can produce tingling, numbness, and “rush” sensations, particularly when symptoms trigger catastrophic interpretation. Clinicians can normalize this physiology without dismissing symptoms.

 

Post-Infectious and Immune Considerations

• Post-viral syndromes: Some patients report symptom onset or worsening after viral illness. While causality is complex, a careful timeline and review of systems can guide appropriate evaluation.
• Autoimmune and inflammatory conditions: Depending on clinical context, screening for systemic inflammatory disease may be appropriate.

 

Environmental Exposure History: A Pragmatic, Non-Sensational Approach

Why ask about indoor dampness and mold?

Indoor dampness and mold are common patient concerns. Even when causality is uncertain, exposure history can inform practical recommendations (ventilation, moisture control, remediation assessment) that may improve overall health and reduce symptom burden. Importantly, a clinician can address environmental fundamentals without claiming that mold is the cause of neurologic disease.

What to assess clinically

• History of water damage, musty odors, visible mold, condensation, and ventilation issues
• Symptom pattern relative to environment (home, workplace, travel)
• Co-exposures (solvents, fuels, occupational chemicals)
• Dietary factors that may influence exposure to certain mycotoxins

 

Practical Exposure-Reduction Fundamentals

General steps may include improving ventilation, reducing indoor humidity, addressing leaks, using appropriate filtration, and seeking professional assessment when significant dampness is suspected. These steps can be framed as “low-regret” interventions that support respiratory and overall health.

 

Urinary Mycotoxin Screening: Potential Utility and Key Limitations

Urinary mycotoxin assays may reflect recent exposure and/or excretion of certain metabolites. Results can be influenced by diet, environment, timing, and individual metabolism. Some patients pursue testing after noticing dampness, musty odors, or symptom fluctuations by environment.

 

Limitations to Communicate Clearly

• Screening, not diagnosis: Elevated results do not prove that mold exposure is the cause of neurologic symptoms.
• Lack of consensus thresholds: Reference ranges and clinical decision points are not universally standardized.
• Dietary confounding: Certain foods may contribute to detectable metabolites independent of indoor exposure.
• Risk of over-attribution: Patients may interpret results as definitive; clinicians should emphasize uncertainty and avoid claims that exceed evidence.

 

A Cautious Clinical Role

When used, urinary mycotoxin screening may serve as a hypothesis-generating tool that prompts:

• more detailed exposure history
• consideration of environmental inspection/remediation evaluation
• reinforcement of general exposure-reduction strategies

In this framing, the test is not positioned as a diagnostic for mold illness or MS risk, but as one data point within a broader clinical picture.

 

Integrative Clinical Approach for Patients with Possible Preclinical MS Concerns

1) Risk stratify and coordinate care

• Encourage neurologic evaluation when indicated
• Clarify what imaging does and does not show
• Consider repeat MRI only when clinically justified
• Provide clear red flags that warrant urgent reassessment (e.g., objective weakness, vision changes, sustained gait disturbance)

2) Address modifiable physiologic contributors

• Replete iron stores when deficient and investigate bleeding etiology
• Correct vitamin D deficiency per standard practice
• Screen and treat B12/thyroid/glucose issues as appropriate

3) Stabilize sleep and autonomic tone

• Behavioral sleep strategies and targeted nutraceutical support when appropriate
• Stress physiology interventions (breathwork, CBT-I, mindfulness-based approaches)

4) Environmental fundamentals

• Moisture control, ventilation, filtration where appropriate
• If significant dampness/mold is suspected, consider professional assessment

5) Shared decision-making language

A useful framing is: “We are ruling out dangerous causes, supporting nervous system resilience, and reducing plausible exposure burdens—without assuming a single cause.” This reduces polarization and supports patient agency.

 

Discussion

Patients with paresthesias and nonspecific WMH occupy a challenging clinical space: symptoms are real and often distressing, yet imaging may be nondiagnostic for MS. A narrative, systems-based approach helps clinicians avoid binary thinking (“MS” vs “not MS”) and instead build a layered plan that addresses common contributors and supports follow-up.

From a neuroimmunology perspective, ongoing research continues to examine environmental and immune mechanisms relevant to MS pathogenesis and prodromal states. This literature supports careful consideration of exposures and immune regulation while also underscoring that individual biomarkers rarely establish causality. Clinicians should avoid overstating the significance of nonspecific WMH or urinary mycotoxin results and instead emphasize structured monitoring, appropriate referral, and correction of modifiable risk factors.

Environmental exposures are a frequent focus for patients seeking explanations for neurologic symptoms. A clinician can engage these concerns responsibly by (1) taking a detailed exposure history, (2) recommending low-regret environmental improvements, and (3) using any screening tests as prompts for further assessment rather than definitive answers. This approach can reduce patient distress, prevent excessive testing cascades, and keep care aligned with both evidence and patient priorities.

 

Conclusion

In patients with paresthesias and nonspecific WMH, MS may remain a concern even when imaging is not diagnostic. A systematic differential diagnosis and stepwise evaluation can identify common, treatable contributors such as iron deficiency and vitamin D deficiency, alongside sleep disruption and stress physiology. Environmental exposure history is reasonable to assess, and urinary mycotoxin screening—if used—should be framed as hypothesis-generating rather than confirmatory. A balanced approach that integrates neurologic risk stratification, modifiable factor correction, environmental fundamentals, and shared decision-making may reduce symptom burden and patient distress while supporting appropriate follow-up.

 

References

1. Frontiers in Immunology. Multiple Sclerosis and Neuroimmunology. (22 July 2025).  https://doi.org/10.3389/fimmu.2025.1625794

 

Author Bio:

Saeid Mushtagh, ND, is a licensed naturopathic physician practicing in North Vancouver, British Columbia, and founder of the Integrative Medical Health (IMH) Clinic. A graduate of the Canadian College of Naturopathic Medicine, Dr. Mushtagh has been in clinical practice for nearly two decades with a focus on integrative primary care, environmental medicine, chronic disease prevention, orthomolecular medicine, and mental health. His clinical interests include complex chronic illness, nutritional and environmental influences on health, and evidence-informed naturopathic approaches to neurological and immune-mediated conditions. He is a member of the British Columbia Naturopathic Association, the Canadian Association of Naturopathic Doctors, the Canadian Society for Orthomolecular Medicine, and the International Network of Integrative Mental Health.